Precision Biotherapeutics: Significance & Challenges

Precision biotherapeutics target disease at its genetic and molecular root, beyond mere symptom management. DBT–BIRAC’s BioE³ Policy prioritises this approach, advancing personalised, gene-based therapies in India.

What are Precision Biotherapeutics?

Personalised, genetic/molecular-profile-based medical interventions using genomics, proteomics, gene editing, mRNA therapy, biologics & AI-driven drug design.
It helps us move from symptom-based care → root-cause correction through targeted, cell-level or gene-level therapeutic mechanisms.
Key Technology Pillars:
- Genomic-Proteomic Profiling: Mutation & biomarker mapping for personalised drug design.
- Gene & Cell Editing: Tools like CRISPR/Cas9, CAR-T, siRNA, AAV vectors for curative therapy.
- mRNA & Nucleic Acid Drugs: Programmable molecular instructions.
- AI-Driven Drug Discovery: Machine-learning-led target modelling & toxicity prediction

Significance of Precision Biotherapeutics

Targeted Cure Potential: Treats root-cause mutations vs symptomatic care. E.g. CRISPR-based thalassemia therapy (Casgevy) approved by the FDA (2023).
NCD Treatment Leap: India faces ~65% deaths from NCDs, demanding precision solutions where standard drugs underperform.
Genomic Fit: High genetic diversity across communities needs India-specific genotype therapies.
Economic & Innovation Play: Global precision medicine market projected >$22B by 2027, offering biotech startup & IP opportunity.

Challenges Associated with Precision Biotherapeutics

High Therapy Cost: Gene & cell therapy prices globally range $0.5M–$2M per patient (e.g., Zolgensma ~$2.1M), making it affordable only for <1% of Indian households based on income data.
Regulatory Ambiguity: India lacks a dedicated CDSCO approval pathway for gene, cell, RNA and genome-edited products, unlike the Japanese fast-track system.
Insufficient Manufacturing Capacity: India has very limited GMP-grade viral-vector and biologics units, causing high import dependence, whereas China has 800+ ongoing gene/cell therapy trials.
Specialised Workforce Shortage: India has few clinical geneticists and genomic medicine specialists, compared to >4,000 board-certified medical geneticists in the US, leading to capability bottlenecks.
Ethical & Data-Privacy Risks: Absence of a specific genomic data protection and biobank law raises risks around IndiGen/GenomeIndia datasets.

Current Affairs

PMF IAS Prelims Magnum Current Affairs Magazines for Prelims

Way Forward

Dedicated Regulatory Pathway: Create a CDSCO Gene–Cell Therapy division with fast-track approvals similar to Japan’s PMDA regenerative model.
Biomanufacturing Expansion: Build viral-vector and biologics GMP hubs through PLI-Biopharma incentives to cut import dependence and therapy cost.
Genomic Data Governance: Enact a bio-banking and consent law aligned with EU-GDPR bioethics rules to prevent genomic data misuse.
Affordability & Insurance Access: Pilot PM-JAY / public-private risk pooling for precision therapies until domestic production reduces prices.
Specialised Talent Pipeline: Start national genomic-medicine fellowships and AI-biotech training, integrated with DBT-IIT-AIIMS translational tracks.

Precision biotherapeutics shift healthcare toward root-cause, personalised, gene-based treatment; with BioE³ policy support, innovation, and strong genomic governance, India can move from symptom care to a future-ready precision health ecosystem.

Reference: The Hindu

PMF IAS Pathfinder for Mains – Question 423

Q. Precision Biotherapeutics marks a shift from population-level treatment to individualised care. Analyse India’s major opportunities and challenges in advancing personalised and gene-editing therapies. (250 Words) (15 Marks)

Approach

Introduction: Write a brief introduction about Precision Biotherapeutics.
Body: Analyse India’s major opportunities, challenges in advancing personalised and gene-editing therapies and way forward.
Conclusion: Emphasis on an integrated approach to a personalised healthcare system.